Figure 4.

Engineered cardiac tissues (ECTs) display canonical inotropic responses to sarcomere modulators and activation of phospholipase C. A, Omecamtiv increased the contractile force with EC₅₀ of 370 nM (n = 9). B, Conversely, increasing doses of MYK461 decreased the contractile force with IC₅₀ of 287 nM (n = 6). C, Treatment with levosimendan increased the contractile force (n = 9) with EC₅₀ of 234 nM. D, Treatment with endothelin-1 which stimulates the activity of phospholipase C (PLC), increased the contractile force with EC₅₀ of 98 pM (n = 6). Data are presented as mean ± SEM.